Beijing, Mar. 30, 2022 —— InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the first patient has been dosed in clinical trial of the Company’s novel RTK (Receptor Tyrosine Kinase) ICP-033 in China.
ICP-033 is a multi-kinase inhibitor mainly targeting discoid in domain receptor 1 (DDR1) and vascular endothelial growth factor receptor (VEGFR) that inhibits angiogenesis and tumor cell invasion, normalizes abnormal blood vessels, and reverses the immunosuppressive state of the tumor microenvironment. Pre-clinical studies have shown that ICP-033 exhibits strong antitumor effects both in vivo and in vitro. ICP-033 will be potentially used as monotherapy and/or in combination with immunotherapy and other targeted drugs to treat liver cancer, renal cell carcinoma, colorectal cancer and other solid tumors.
Dr. Jasmine Cui, Co-Founder, Chairwoman and CEO of InnoCare, said, “We feel encouraging to see the clinical progress of another new drug candidate for the treatment of solid tumors. ICP-033 will further strengthen our pipeline in solid tumors. We will advance the clinical development to provide a competitive treatment solution for the treatment of solid tumors.”
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, New Jersey and Boston.